Merck KGaA amps up next-gen antibody pact with Ablynx

Merck KGaA R&D subsidiary Merck Serono will provide $35 million over four years to fund a dedicated unit that will apply the Belgian biotech's "Nanobody" approach to all of Merck's core disease ar…
Read the full story: FierceBiotech News